• Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis
• Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%
• Income from operations increased 15%; non-GAAP income from operations up 19%

Resmed Inc. announced results for its quarter ended September 30, 2025. Revenue grew by 8% on a constant currency basis, driven by increased demand for the company's portfolio of sleep devices, masks and accessories. Gross margin increased by 290 basis points primarily due to manufacturing and logistics efficiencies and component cost improvements. Non-GAAP gross margin increased by 280 basis points due to the same factors. Selling, general, and administrative expenses increased by 7% on a constant currency basis, mainly due to additional expenses associated with the VirtuOx acquisition, employee costs, and marketing and technology investments. The company recorded $16 million of restructuring-related charges following company-wide workforce planning activities aligned with its 2030 strategic priorities. Income from operations increased by 15% and non-GAAP income from operations increased by 19%. Net income for the quarter was $349 million, and non-GAAP net income increased by 15% to $375 million. Diluted earnings per share was $2.37, and non-GAAP diluted earnings per share increased by 16% to $2.55. Operating cash flow for the quarter was $457 million.

Resmed expects to deliver strong, sustainable, profitable growth in fiscal year 2026 as it provides access to life-changing care for the billions of people worldwide who need its market-leading healthcare solutions.